NO962127L - Isoksakinforbindelser som anti-innflammatoriske midler - Google Patents

Isoksakinforbindelser som anti-innflammatoriske midler

Info

Publication number
NO962127L
NO962127L NO962127A NO962127A NO962127L NO 962127 L NO962127 L NO 962127L NO 962127 A NO962127 A NO 962127A NO 962127 A NO962127 A NO 962127A NO 962127 L NO962127 L NO 962127L
Authority
NO
Norway
Prior art keywords
compounds
isoxacin
inflammatory agents
pdeiv
relates
Prior art date
Application number
NO962127A
Other languages
English (en)
Norwegian (no)
Other versions
NO962127D0 (no
Inventor
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO962127D0 publication Critical patent/NO962127D0/no
Publication of NO962127L publication Critical patent/NO962127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO962127A 1993-11-26 1996-05-24 Isoksakinforbindelser som anti-innflammatoriske midler NO962127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15724893A 1993-11-26 1993-11-26
US26208694A 1994-06-17 1994-06-17
PCT/IB1994/000333 WO1995014681A1 (en) 1993-11-26 1994-10-26 Isoxazoline compounds as antiinflammatory agents

Publications (2)

Publication Number Publication Date
NO962127D0 NO962127D0 (no) 1996-05-24
NO962127L true NO962127L (no) 1996-05-24

Family

ID=26853945

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962127A NO962127L (no) 1993-11-26 1996-05-24 Isoksakinforbindelser som anti-innflammatoriske midler

Country Status (24)

Country Link
US (1) US5716967A (de)
EP (1) EP0730588B1 (de)
JP (1) JP2802547B2 (de)
KR (1) KR0182324B1 (de)
CN (1) CN1046274C (de)
AT (1) ATE154932T1 (de)
AU (1) AU687452B2 (de)
BR (1) BR9408174A (de)
CA (1) CA2176255C (de)
CO (1) CO4180606A1 (de)
CZ (1) CZ283564B6 (de)
DE (1) DE69404044T2 (de)
DK (1) DK0730588T3 (de)
EG (1) EG20693A (de)
ES (1) ES2104424T3 (de)
FI (1) FI945557L (de)
GR (1) GR3024133T3 (de)
HU (1) HUT76784A (de)
IL (1) IL111670A (de)
NO (1) NO962127L (de)
NZ (1) NZ274244A (de)
PE (1) PE33495A1 (de)
PL (1) PL314605A1 (de)
WO (1) WO1995014681A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE69503769T2 (de) * 1994-03-09 1998-12-03 Pfizer Inc., New York, N.Y. Isoxazoline verbindung zur hemmung tnf-freigabe
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (de) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Kondensierte polycyclische 2-aminopyrimidinderivate, ihre herstellung und verwendung als proteininhibitoren von tyrosinkinase
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6022977A (en) 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1212309B1 (de) * 1999-09-17 2004-08-18 LG Chem Investment, Ltd. Caspase-hemmer
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
EP1389468A4 (de) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co Zusammensetzungen zur förderung der knochenfrakturheilung
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
BR0209774A (pt) * 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
AU2002314944B2 (en) * 2001-06-08 2008-03-06 Cytokine Pharmasciences, Inc. Isoxazoline compounds having MIF antagonist activity
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US7125870B2 (en) * 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2005219788B2 (en) 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
US20050250826A1 (en) * 2004-03-26 2005-11-10 Thais Sielecki-Dzurdz Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
JP5336175B2 (ja) * 2005-03-15 2013-11-06 ガニアル・イミュノセラピューティクス・インコーポレーテッド 免疫調整剤活性を有する化合物
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
EP1879884B1 (de) * 2005-05-03 2010-08-25 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren auf azolbasis
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2063905B1 (de) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
EA024512B1 (ru) 2011-03-31 2016-09-30 Байер Интеллектуэль Проперти Гмбх Гербицидно и фунгицидно действующие 3-фенилизоксазолин-5-карбоксамиды и 3-фенилизоксазолин-5-тиоамиды
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
ES2744245T3 (es) 2012-04-17 2020-02-24 Geneone Life Science Inc Compuestos que tienen actividad inmunomoduladora
DK2900645T3 (da) * 2012-09-25 2019-10-14 Bayer Cropscience Ag Herbicidt aktive 3-phenylisoxazolinderivater
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
CN103381157A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone B在治疗慢性阻塞性肺疾病的药物中的应用
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3134401B1 (de) * 2014-04-22 2018-06-13 Novartis AG Isoxazoline hydroxamsäurederivate als lpxc inhibitoren
DK3638665T3 (da) 2017-06-13 2021-10-11 Bayer Ag Herbicidt virksomme 3-phenylisoxazolin-5-carboxamider af tetrahydro- og dihydrofurancarboxylsyrer og -estere
US11613522B2 (en) 2017-06-13 2023-03-28 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxamides
JP7198519B2 (ja) 2017-08-17 2023-01-04 バイエル・アクチエンゲゼルシヤフト シクロペンチルカルボン酸類及びエステル類の除草活性３－フェニル－５－トリフルオロメチルイソオキサゾリン－５－カルボキサミド類
CA3089286A1 (en) 2018-01-25 2019-08-01 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives
ES2950189T3 (es) 2019-03-12 2023-10-05 Bayer Ag 3-fenilisoxazolina-5-carboxamidas de ésteres de ácido ciclopentenilcarboxílico que contienen s herbicidas
EP4706758A3 (de) 2019-05-21 2026-05-06 Ardelyx, Inc. Verfahren zur hemmung des phosphattransports

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
JPS62103070A (ja) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US4731382A (en) * 1986-12-29 1988-03-15 Bristol-Myers Company Lipoxygenase inhibitory phenylalkanohydroxamic acids
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
IL92915A0 (en) * 1989-01-05 1990-09-17 Ciba Geigy Ag Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
DE3939010A1 (de) * 1989-11-25 1991-05-29 Hoechst Ag Isoxazoline, verfahren zu ihrer herstellung und ihre verwendung als pflanzenschuetzende mittel
JP2787602B2 (ja) * 1990-01-24 1998-08-20 大鵬薬品工業株式会社 イソキサゾリン誘導体
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5140047A (en) * 1991-05-03 1992-08-18 Smithkline Beecham Corporation Lipoxygenase inhibitors
GB9215921D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
WO1994018158A1 (en) * 1993-02-15 1994-08-18 Pfizer Inc. Spiroalkylhydroxyureas for use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
CA2176255A1 (en) 1995-06-01
PE33495A1 (es) 1995-10-27
FI945557A7 (fi) 1995-05-27
AU687452B2 (en) 1998-02-26
PL314605A1 (en) 1996-09-16
CZ283564B6 (cs) 1998-05-13
NZ274244A (en) 1997-09-22
AU7821894A (en) 1995-06-13
CN1046274C (zh) 1999-11-10
GR3024133T3 (en) 1997-10-31
IL111670A (en) 1998-08-16
DE69404044T2 (de) 1997-10-16
JPH09500147A (ja) 1997-01-07
CZ151096A3 (en) 1997-01-15
US5716967A (en) 1998-02-10
HUT76784A (en) 1997-11-28
KR0182324B1 (ko) 1999-05-01
DK0730588T3 (da) 1997-12-08
FI945557L (fi) 1995-05-27
ATE154932T1 (de) 1997-07-15
JP2802547B2 (ja) 1998-09-24
NO962127D0 (no) 1996-05-24
BR9408174A (pt) 1997-05-27
KR960705795A (ko) 1996-11-08
HU9601412D0 (en) 1996-07-29
EP0730588B1 (de) 1997-07-02
DE69404044D1 (de) 1997-08-07
CO4180606A1 (es) 1995-06-07
IL111670A0 (en) 1995-01-24
WO1995014681A1 (en) 1995-06-01
CN1136314A (zh) 1996-11-20
CA2176255C (en) 1999-02-23
FI945557A0 (fi) 1994-11-25
EG20693A (en) 1999-11-30
EP0730588A1 (de) 1996-09-11
ES2104424T3 (es) 1997-10-01

Similar Documents

Publication Publication Date Title
NO962127L (no) Isoksakinforbindelser som anti-innflammatoriske midler
DK0730587T3 (da) 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler
NO952178L (no) Katekol-dietere som selektive PDEIV inhibitekorer
JOP20210179A1 (ar) مثبطات إيميدازو[1، 2-b] بيريدازين IL-17A
DK0730579T3 (da) Substituerede indoler som inhibitorer af phosphodiesterase-type-IV
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
NO20072918L (no) Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
BRPI0511383A (pt) composto, composição farmacêutica, uso de composto, método para o tratamento de um sujeito que sofre com uma condição patológica ou doença susceptìvel de melhora por inibição de fosfodiesterase 4 e produto combinado
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO963746D0 (no) Isoksalin-forbindelser som inhibitorer for frigivning av TNF
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2021067569A8 (en) Substituted 1, 6-naphthyridine inhibitors of cdk5
NO20055752L (no) N-ureidoalkyl-piperidiner som modulerer forbindelser av kjemokinreseptor-aktivitet
DK1246825T3 (da) Kondenserede pyrrolforbindelser, farmaceutiske midler indeholdende dem og anvendelse deraf
DK0752990T3 (da) Benzisothiazolderivater som inhibitorer af 5-lipoxygenasebiosyntese
EA202191464A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ИНГИБИТОРЫ IL-17A